Company profile
Ultragenyx Pharmaceutical Inc.
NASDAQ: RARE · Healthcare · Biotechnology
#189 of 1,418 Healthcare companies by revenue66th-percentile growth
EA Score
58CFH 42DQ 68GM 74SS 78
v0.1 · 65/100 weight · provisional
↑ market scale, workforce scale · ↓ Piotroski F, balance-sheet leverage
Methodology →Revenue TTM
$669.4M
Rev growth YoY (TTM)
+13.3%
Net income (FY)
-$575.0M
Employees
1,371
as of 2026-08-08
Market cap
$2.6B
as of 2026-08-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$673.0M$673.0M2025
Net income-$575.0M-$575.0M2025
Operating income-$535.0M-$535.0M2025
Total assets$1.5B$1.5B2025
Liabilities$1.6B$1.6B2025
Equity-$80.0M-$80.0M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product55%
Royalty45%
By geography
North America56%
Latin America25%
EMEA16%
Asia Pacific3%
The read
What is Ultragenyx Pharmaceutical Inc.’s revenue?
Ultragenyx Pharmaceutical Inc. booked $673.0M in FY2025 revenue, growing 20% year over year — faster than most Healthcare companies we track, at a -85.4% net margin.
Peers · Healthcare
Supernus Pharmaceuticals, Inc.76B+Sienna Senior Living Inc.75B+Avanos Medical, Inc.73BCresco Labs Inc.37DDoximity, Inc.73B10x Genomics, Inc.67BNeighbors
Marin →Key facts
CEOEmil D. Kakkis
SectorHealthcare
IndustryBiotechnology
HeadquartersNovato, CA
ExchangeNASDAQ: RARE
Employees1,371
IPO date2014-01-31
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.